Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Hisamitsu: Sales Up 5% Driven by Mohrus Series
January 25, 2010
- Korosho to Present Bill to Amend Preventive Vaccination Law
January 25, 2010
- Merck Serono to Increase Market Share for Gonalef, Saizen
January 25, 2010
- Blopress Remains No. 1 for 6 Terms in a Row: Domestic Drugs Sales Ranking
January 25, 2010
- No Serious Concern about Safety of New-Type Flu Vaccines Made in Japan
January 25, 2010
- 3 Novartis A (H1N1) 2009 Flu Vaccines Prequalified by WHO
January 18, 2010
- DSP Applies for Lurasidone in the US
January 18, 2010
- ON THE MOVE
January 18, 2010
- Teijin Pharma Applies for TMX-67 in Japan
January 18, 2010
- Common Approval System Needed in Asia: Mr Shoda
January 18, 2010
- Herceptin Receives Positive Opinion for Advanced Stomach Cancer from CHMP
January 18, 2010
- Top Management Stresses Need to Develop New Products in New Year's Speeches
January 18, 2010
- Industry Must Make Further Investment in R&D to Introduce Better Pricing System
January 18, 2010
- Reform of Distribution Practices and Drug Pricing System Are Two Sides of the Same Coin: Mr Bessho
January 18, 2010
- Reorganization of Generics Industry to Progress: Mr Sawai
January 18, 2010
- Responses to New Pricing System Most Important Challenge for Wholesalers: Mr Kohno
January 18, 2010
- NJIHK to Start Hansha's MS Certification System
January 18, 2010
- Eisai Completes Acquisition of AkaRx
January 18, 2010
- Japan, China, South Korea to Start Joint Studies on Ethnic Differences
January 18, 2010
- Kyowa Kirin Licenses Bardoxolone from Reata
January 18, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…